Dr. Abid on Sequencing Pirtobrutinib After CAR-T
By Melissa Badamo, Patrick Daly, Bilal Abid, MD - Last Updated: October 4, 2024Bilal Abid, MD, of the University of Texas Health Science Center at Houston, discusses how to approach sequencing pirtobrutinib after chimeric antigen receptor (CAR) T-cell therapy for the management of hematologic malignancies at the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Advertisement
Advertisement
Related Posts
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.